Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01701960 |
Recruitment Status :
Withdrawn
(no time)
First Posted : October 5, 2012
Last Update Posted : March 20, 2015
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | October 3, 2012 | |||
First Posted Date | October 5, 2012 | |||
Last Update Posted Date | March 20, 2015 | |||
Study Start Date | November 2012 | |||
Estimated Primary Completion Date | February 2014 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures |
change in blood pressure [ Time Frame: over the course of surgery ] | |||
Original Primary Outcome Measures | Not Provided | |||
Change History | ||||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery | |||
Official Title | Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery | |||
Brief Summary | 1% Lidocaine with 1:100,000 to 1:200,000 of epinephrine is routinely injected into the nasal mucosa during nasal surgery to reduce patient blood loss and improve the surgical field and visibility. Typically 1% lidocaine with 1:100,000 of epinephrine is used in nasal surgery. However, 1 % lidocaine with 1:200,000 (which is a more dilute solution of epinephrine) is also used. This latter dose theoretically should have a lesser effect on cardiac stimulation which increases the heart rate and blood pressure at the time of surgery. The nasal mucosa has excellent absorbing ability which is great for the application of drugs but there is concern for systemic absorption and side effects. Potential serious side effects can occur with local injection such as hypertension, tachycardia, and cardiac arrhythmias. These side effects occur mainly through the absorption of epinephrine. It is the goal of this study to see if a weaker concentration of epinephrine (1:200,000) can maintain a good surgical field with a decrease in hemodynamic side effects. | |||
Detailed Description | Objective- To evaluate the effect of 1% lidocaine with 1:200,000 of epinephrine on hemodynamic measures and bleeding in the surgical field in patients undergoing nasal surgery compared to 1% lidocaine with 1:100,000. Recruitment plan- Patients undergoing general anesthetic for nasal surgery (septoplasty or sinus surgery) will be asked to participate in this study. All patients undergoing nasal surgery are injected with local anesthetic into the nasal mucosa after induction of general anesthetic. Those patients who agree to participate in the study will be randomized into 2 groups (injection either 1 % lidocaine with 1:100,000 or 1:200,000 of epinephrine). Procedures
Alternatives- Subjects can refuse to participate in the study. If subjects refuse to participate in the study they will still be injected with 1% lidocaine with 1:200,000 of epinephrine which is standard of care Data analysis- data will be compiled and statistical analysis will be made using PRISM software. |
|||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Subjects ages 16-75 undergoing routine nasal surgery which will include septoplasty and sinus surgery | |||
Condition |
|
|||
Intervention | Not Provided | |||
Study Groups/Cohorts |
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Withdrawn | |||
Actual Enrollment |
0 | |||
Original Estimated Enrollment |
40 | |||
Actual Study Completion Date | August 2014 | |||
Estimated Primary Completion Date | February 2014 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | 16 Years to 75 Years (Child, Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01701960 | |||
Other Study ID Numbers | 5120227 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Kristin Seiberling, MD, Loma Linda University | |||
Study Sponsor | Loma Linda University | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | Loma Linda University | |||
Verification Date | March 2015 |